CSI Market
Sign In | Register

Allogene Therapeutics Inc (ALLO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ALLO Annual Cash Flow →
This cash flow overview for Allogene Therapeutics Inc spans from Jun 30 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-85.28
Depreciation & amortization5.51
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation20.71
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Investment Income Net Amortization Of Discount And Premium-0.89
Lease And Rental Expense-
Income Tax Expense Benefit-
Equity Method Investment Other Than Temporary Impairment-
Operating Lease Expense1.07
Noncash Collaboration Revenue-
Increase Decrease In Operating Lease Liability-2.20
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable1.69
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-2.82
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-23.62
Other Working Capital0.75
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities38.15
Discontinued operations0.00
Net Cash flow from Operating Activities-44.91
Investing Activities
Capital Expenditures-0.16
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities108.43
Short-term Investments Acq.0.00
Payments for Leasing Costs, Commissions, and Tenant Improvements-6.53
Proceeds From Payments For Sale Of Debt Securities Available For Sale-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-285.42
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Assets, Investing Activities0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net6.53
Discontinued operations0.00
Net Cash Flow from Investing Activities-177.15
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.45
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net208.54
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Options-
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Early Exercise Of Stock Options-
Proceeds From Grant Awards-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities208.99
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-45.07
Total Cash Flow-13.06
4 historic quarters locked

Sign in to unlock the full Allogene Therapeutics Inc cash flow history.

Sign In Create Free Account

About Allogene Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-056213

Figures are derived from filed reports and may be restated. Historical data is subject to revision.